Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

Home test to predict postpartum depression

Official title: A Prospective Validation of the Enlighten Device in Predicting Postpartum Depression Using At-Home Sample Collection in Both Blood and Saliva

Run by University of Virginia · NCT07186309 · Data updated 2026-11-12

This project will test whether the Enlighten blood or saliva test taken in late pregnancy can predict which pregnant women (age 18+, singleton pregnancies enrolled before 30 weeks) will develop postpartum depression in the first three months after birth.

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment1000 (estimated)
SponsorUniversity of Virginia
Academic / other
Locations1 site (Charlottesville, Virginia)
StatusRecruiting
StartedNovember 20, 2025
Main results expectedAugust 2029
Study endsAugust 2030
Registry record updatedNovember 28, 2025
Trial IDNCT07186309 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are pregnant women aged 18 or older with a singleton pregnancy who can consent in English and enroll before 30 weeks' gestation.

Probably not a fit

Women beyond the enrollment window (past 30 weeks), with multifetal pregnancies, who cannot consent in English, or who are already diagnosed and effectively treated for PPD are less likely to benefit from this predictive test.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational project will prospectively validate the Enlighten diagnostic test by collecting blood and saliva samples from about 1,000 pregnant women enrolled before 30 weeks' gestation and following them through three months postpartum to measure true and false positive and negative rates. The study will compare biomarker and algorithm performance in blood versus saliva and will include a week-6 postpartum sample to identify women who are currently experiencing PPD. Participants provide samples and symptom outcome data, with the primary outcome based on postpartum depression status within three months. The effort is led by the University of Virginia with collaborators including Mayo Clinic and Dionysus Health.

Why it matters

Potential benefit: If successful, the test could help identify women at high risk for postpartum depression earlier so they can get monitoring or treatment sooner.

How similar studies have gone: Prior small studies of biomarker-based PPD prediction have shown promising but limited results, so this larger prospective validation is intended to provide stronger evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* subject must be pregnant (singleton pregnancy)
* \<30 weeks' gestation, age 18 or above
* able to provide written consent in English

Exclusion Criteria:

* The study team and/or PI may exclude anyone deemed unsafe to participate in the protocol.

Where it's running

  • University of Virginia
    Charlottesville, Virginia, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.